| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.079 | 0.02 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | -0.093 | 0.02 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | -0.069 | 0.02 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.03 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | 0.08 | 0.03 |
| mRNA | A-770041 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.03 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | -0.18 | 0.03 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.076 | 0.03 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | -0.089 | 0.03 |